Abstract
The structural analysis of class B G protein-coupled receptors (GPCR), cell surface proteins responding to peptide hormones, has until recently been restricted to the extracellular domain (ECD). Corticotropin-releasing factor receptor type 1 (CRF1R) is a class B receptor mediating stress response and also considered a drug target for depression and anxiety. Here we report the crystal structure of the transmembrane domain of human CRF1R in complex with the small-molecule antagonist CP-376395 in a hexagonal setting with translational non-crystallographic symmetry. Molecular dynamics and metadynamics simulations on this novel structure and the existing TMD structure for CRF1R provides insight as to how the small molecule ligand gains access to the induced-fit allosteric binding site with implications for the observed selectivity against CRF2R. Furthermore, molecular dynamics simulations performed using a full-length receptor model point to key interactions between the ECD and extracellular loop 3 of the TMD providing insight into the full inactive state of multidomain class B GPCRs.
Keywords: CRF1R, translational non-crystallographic symmetry, molecular dynamics, GPCR, metadynamics, CP-376395.
Graphical Abstract
Current Molecular Pharmacology
Title:Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures
Volume: 10
Author(s): Andrew S. Dore, Andrea Bortolato, Kaspar Hollenstein, Robert K.Y. Cheng, Randy J. Read and Fiona H. Marshall*
Affiliation:
- Heptares Therapeutics Ltd, BioPark, Broadwater Road, Welwyn Garden City, Herts, AL7 3AX,United Kingdom
Keywords: CRF1R, translational non-crystallographic symmetry, molecular dynamics, GPCR, metadynamics, CP-376395.
Abstract: The structural analysis of class B G protein-coupled receptors (GPCR), cell surface proteins responding to peptide hormones, has until recently been restricted to the extracellular domain (ECD). Corticotropin-releasing factor receptor type 1 (CRF1R) is a class B receptor mediating stress response and also considered a drug target for depression and anxiety. Here we report the crystal structure of the transmembrane domain of human CRF1R in complex with the small-molecule antagonist CP-376395 in a hexagonal setting with translational non-crystallographic symmetry. Molecular dynamics and metadynamics simulations on this novel structure and the existing TMD structure for CRF1R provides insight as to how the small molecule ligand gains access to the induced-fit allosteric binding site with implications for the observed selectivity against CRF2R. Furthermore, molecular dynamics simulations performed using a full-length receptor model point to key interactions between the ECD and extracellular loop 3 of the TMD providing insight into the full inactive state of multidomain class B GPCRs.
Export Options
About this article
Cite this article as:
Dore S. Andrew, Bortolato Andrea, Hollenstein Kaspar, Cheng K.Y. Robert, Read J. Randy and Marshall H. Fiona*, Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures, Current Molecular Pharmacology 2017; 10 (4) . https://dx.doi.org/10.2174/1874467210666170110114727
DOI https://dx.doi.org/10.2174/1874467210666170110114727 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy
Current Medicinal Chemistry Small Molecule Antagonists of the Chemokine Receptor CCR5
Current Topics in Medicinal Chemistry Neuropeptidomics: Improvements in Mass Spectrometry Imaging Analysis and Recent Advancements
Current Protein & Peptide Science Commentary: (Research Highlights: “MiRNAcles” in Brain)
CNS & Neurological Disorders - Drug Targets Recent Updates on the Association Between Alzheimer’s Disease and Vascular Dementia
Medicinal Chemistry Role of Prolyl Endopeptidase in Intracellular Transport and Protein Secretion
CNS & Neurological Disorders - Drug Targets The Management and Outcomes of Pharmacological Treatments for Tinnitus
Current Neuropharmacology Design, Synthesis, and Biological Evaluation of Novel Tetramethylpyrazine- nitrone Derivatives as Antioxidants
Letters in Drug Design & Discovery Opportunities to Discover Genes Regulating Depression and Antidepressant Response from Rodent Behavioral Genetics
Current Pharmaceutical Design Applications of Lipid based Formulation Technologies in the Delivery of Biotechnology-based Therapeutics
Current Pharmaceutical Biotechnology Stereoselectivity in Drug Metabolism: Molecular Mechanisms and Analytical Methods
Current Drug Metabolism Autoantibodies in Autoimmune Diseases
Current Pharmaceutical Design Patented Herbal Formulations and their Therapeutic Applications
Recent Patents on Drug Delivery & Formulation Preface [Hot topic: Current Pharmacotherapeutic Approaches to the Treatment of Cognitive Impairment in Alzheimers Disease and Related Disorders (Executive Editor : Bernd Ibach)]
Current Pharmaceutical Design Infectious Agents and Neurodegenerative Diseases: Exploring the Links
Current Topics in Medicinal Chemistry Time Perception Distortion in Neuropsychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Ryanodine Receptor: A Pivotal Ca2+ Regulatory Protein and Potential Therapeutic Drug Target
Current Drug Targets Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology CDK9: Therapeutic Perspective in HCC Therapy
Current Cancer Drug Targets Non-Peptide Vasopressin V1b Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related Disorders
Current Pharmaceutical Design